Your session is about to expire
← Back to Search
atomoxetine for Neurogenic Orthostatic Hypotension (NETAF Trial)
NETAF Trial Summary
This trial will study whether atomoxetine is an effective drug for treating symptoms associated with neurogenic orthostatic hypotension in patients with autonomic failure.
- Neurogenic Orthostatic Hypotension
NETAF Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.NETAF Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
How many participants are enrolled in this clinical experiment?
"Currently, this research trial is not accepting new participants. It was first published on the 29th of August in 2016 and last updated on the 22nd of August 2022. For those looking for alternatives, 115 clinical trials related to hypotension are actively enrolling patients as well as 12 studies centred around atomoxetine."
Does this trial accept individuals aged fifty and above as participants?
"Patients between the ages of 40 and 80 are eligible to join this clinical trial. Additionally, 12 studies designed for participants under 18 years old have been conducted while 100 studies with patients over 65 exist."
Is there still an opportunity for enrolment in this research endeavor?
"Unfortunately, this trial is not taking on patients at the moment. It was first published August 29th 2016 and last updated on 8/22/2022. On the other hand, there are 115 clinical trials searching for volunteers with hypotension and 12 studies looking to enroll participants that take atomoxetine."
Might I be a suitable candidate for this research endeavor?
"In order to be part of this study, interested participants should have low blood pressure and meet the age criteria between 40-80 years old. The total number of patients accepted will amount to 48 individuals."
Has the FDA sanctioned atomoxetine for use in patients?
"Data on atomoxetine's safety, but not efficacy, has been collected in a Phase 2 trial. As such, this drug was awarded an estimation of 2 for its overall safety profile."
What other trials have been conducted to assess the efficacy of atomoxetine?
"Initially, atomoxetine was researched at Vanderbilt University Autonomic Dysfunction Center in 1997. Since then, 18383 trials have been completed and there are currently 12 active clinical studies mainly located in New york City."
Share this study with friends
Copy Link
Messenger